Huadong Medicine (000963.SZ) Subsidiary's Marketing Application for Cavilaglutide Tromethamine Tablets Accepted

Stock News11-03

Huadong Medicine Co.,Ltd. (000963.SZ) has announced that on November 2, 2026, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Zhongmei Huadong") received a Notice of Acceptance issued by the National Medical Products Administration (NMPA).

The marketing application for cavilaglutide tromethamine tablets (development code: HDM1002 tablets), an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for long-term weight management in adults has been accepted.

Cavilaglutide tromethamine tablets are an oral small-molecule GLP-1 receptor full agonist independently developed by Zhongmei Huadong with global intellectual property rights, featuring oral activity, high potency, and high selectivity.

The product employs a once-daily oral dosing regimen, and its absorption is unaffected by food and water intake, requiring no strict fasting conditions or post-dose waiting time, offering flexible and convenient administration.

As of September 30, 2026, the company's total direct R&D investment in the cavilaglutide tromethamine tablet project (including weight management and glucose-lowering indications) amounted to approximately RMB 507 million (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment